Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma: Review of technology appraisal guidance 37

NICE technology appraisals [TA137] Published date:

This guidance updates and replaces NICE technology appraisal 37 (published in May 2002).

The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.

Get involved